- Home
- NX vs NUVB Comparison
NX vs NUVB Comparison
Compare NX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NX
- NUVB
- Stock Information
- Founded
- NX 1927
- NUVB 2018
- Country
- NX United States
- NUVB United States
- Employees
- NX N/A
- NUVB N/A
- Industry
- NX Metal Fabrications
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- NX Industrials
- NUVB Health Care
- Exchange
- NX Nasdaq
- NUVB Nasdaq
- Market Cap
- NX 1.1B
- NUVB 959.2M
- IPO Year
- NX N/A
- NUVB N/A
- Fundamental
- Price
- NX $22.90
- NUVB $2.59
- Analyst Decision
- NX Strong Buy
- NUVB Strong Buy
- Analyst Count
- NX 1
- NUVB 6
- Target Price
- NX $38.00
- NUVB $7.00
- AVG Volume (30 Days)
- NX 716.4K
- NUVB 2.8M
- Earning Date
- NX 03-06-2025
- NUVB 02-27-2025
- Dividend Yield
- NX 1.41%
- NUVB N/A
- EPS Growth
- NX N/A
- NUVB N/A
- EPS
- NX 0.90
- NUVB N/A
- Revenue
- NX $1,277,862,000.00
- NUVB $2,162,000.00
- Revenue This Year
- NX $50.17
- NUVB N/A
- Revenue Next Year
- NX $2.87
- NUVB $369.72
- P/E Ratio
- NX $25.44
- NUVB N/A
- Revenue Growth
- NX 13.03
- NUVB N/A
- 52 Week Low
- NX $21.48
- NUVB $1.43
- 52 Week High
- NX $39.31
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- NX 34.56
- NUVB 44.55
- Support Level
- NX $21.48
- NUVB $2.44
- Resistance Level
- NX $24.22
- NUVB $3.46
- Average True Range (ATR)
- NX 0.81
- NUVB 0.23
- MACD
- NX -0.05
- NUVB -0.01
- Stochastic Oscillator
- NX 36.01
- NUVB 14.29
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).